Allogene Therapeutics (ALLO) Long-Term Investments (2018 - 2026)
Allogene Therapeutics (ALLO) posted Long-Term Investments of $8.0 million for Q4 2025, down 67.76% sequentially from $24.9 million in Q3 2025, and down 90.03% YoY from $80.7 million in Q4 2024.
Allogene Therapeutics (ALLO) Long-Term Investments (2018 - 2026) Analysis & Trends
Allogene Therapeutics has reported Long-Term Investments for 8 years, with the latest figure at $8.0 million in Q4 2025.
- Quarterly Long-Term Investments fell 90.03% year-over-year to $8.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $8.0 million (down 90.03% YoY) and the FY2025 annual result came in at $8.0 million, down 90.03% from the prior year.
- Long-Term Investments slipped to $8.0 million in Q4 2025 per ALLO's latest filing, from $24.9 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $378.2 million in Q3 2021 and troughed at $1.1 million in Q2 2024.
- A 5-year average of $66.9 million and a median of $24.9 million in 2025 frame the typical range for Long-Term Investments.
- The sharpest annual moves came in 2021 and 2024: Long-Term Investments soared 8275.16% in 2021, then sank 97.84% in 2024.
- Over 5 years, Long-Term Investments stood at $352.2 million in 2021, then sank by 95.08% to $17.3 million in 2022, then surged by 85.77% to $32.2 million in 2023, then soared by 150.77% to $80.7 million in 2024, then plunged by 90.03% to $8.0 million in 2025.
- According to Business Quant data, Long-Term Investments over the past three periods registered $8.0 million, $24.9 million, and $29.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Allogene Therapeutics | 707.96 Mn | 707.96 Mn | - | 90.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 90.99 Mn |
| Dec 31, 2025 | 8.04 Mn |
| Sep 30, 2025 | 24.94 Mn |
| Jun 30, 2025 | 29.51 Mn |
| Mar 31, 2025 | 55.51 Mn |
| Dec 31, 2024 | 80.67 Mn |
| Sep 30, 2024 | 111.82 Mn |
| Jun 30, 2024 | 1.13 Mn |
| Mar 31, 2024 | 2.70 Mn |
| Sep 30, 2023 | 32.17 Mn |
| Jun 30, 2023 | 52.59 Mn |
| Mar 31, 2023 | 14.38 Mn |
| Dec 31, 2022 | 17.32 Mn |
| Sep 30, 2022 | 20.95 Mn |
| Jun 30, 2022 | 23.67 Mn |
| Mar 31, 2022 | 27.66 Mn |
| Dec 31, 2021 | 352.18 Mn |
| Sep 30, 2021 | 378.22 Mn |
| Jun 30, 2021 | 18.80 Mn |
| Mar 31, 2021 | 19.35 Mn |